Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,058Revenue (TTM) $M175Net Margin (%)14.9Altman Z-Score9.1
Enterprise Value $M1,004EPS (TTM) $0.5Operating Margin %15.4Piotroski F-Score5
P/E(ttm)45.5Beneish M-Score-1.7Pre-tax Margin (%)15.6Higher ROA y-yN
Price/Book7.510-y EBITDA Growth Rate %--Quick Ratio1.5Cash flow > EarningsY
Price/Sales6.35-y EBITDA Growth Rate %--Current Ratio1.7Lower Leverage y-yY
Price/Free Cash Flow38.8y-y EBITDA Growth Rate %-26.9ROA % (ttm)14.1Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)21.8Less Shares Outstanding y-yY
Payout Ratio %--Shares Outstanding M49.5ROIC % (ttm)37.9Gross Margin Increase y-yN

Gurus Latest Trades with SUPN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SUPNJoel Greenblatt 2016-06-30 Reduce$15.12 - $20.37
($17.7)
$ 21.3821%Reduce -29.04%12,455
SUPNRobert Bruce 2016-03-31 Reduce-0.12%$10.13 - $15.65
($13.02)
$ 21.3864%Reduce -11.78%224,581
SUPNJoel Greenblatt 2016-03-31 Reduce$10.13 - $15.65
($13.02)
$ 21.3864%Reduce -48.08%17,552
SUPNRobert Bruce 2015-12-31 Reduce-0.57%$12.78 - $18.86
($15.48)
$ 21.3838%Reduce -35.48%254,581
SUPNJoel Greenblatt 2015-12-31 Reduce$12.78 - $18.86
($15.48)
$ 21.3838%Reduce -13.63%33,808
SUPNRobert Bruce 2015-09-30 Reduce-1.5%$13.62 - $21.26
($18.58)
$ 21.3815%Reduce -43.19%394,581
SUPNJoel Greenblatt 2015-09-30 Reduce-0.01%$13.62 - $21.26
($18.58)
$ 21.3815%Reduce -55.66%39,142
SUPNGeorge Soros 2015-06-30 Sold Out -0.01%$12.09 - $18.37
($14.2)
$ 21.3851%Sold Out0
SUPNJoel Greenblatt 2015-06-30 Add0.01%$12.09 - $18.37
($14.2)
$ 21.3851%Add 111.74%88,267
SUPNGeorge Soros 2015-03-31 Buy 0.01%$8.18 - $12.09
($9.45)
$ 21.38126%New holding107,308
SUPNJoel Greenblatt 2015-03-31 Buy $8.18 - $12.09
($9.45)
$ 21.38126%New holding41,686
SUPNRobert Bruce 2014-12-31 Add0.68%$7.49 - $9.49
($8.4)
$ 21.38155%Add 73.65%694,581
SUPNRobert Bruce 2014-09-30 Add0.73%$7.99 - $11.13
($8.98)
$ 21.38138%Add 300.00%400,000
SUPNRobert Bruce 2014-06-30 Buy 0.25%$7.32 - $10.85
($8.88)
$ 21.38141%New holding100,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SUPN is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


SUPN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
PATRICK GREGORY SVP, CFO 2016-07-14Sell3,395$22-2.82view
Bhatt Padmanabh P.Sr. VP of IP, CSO 2016-04-11Sell30,762$16.4929.65view
Bhatt Padmanabh P.Sr. VP of IP, CSO 2015-12-09Sell14,238$14.943.49view
BARRETT M JAMESDirector 2015-12-08Sell212,970$14.5646.84view
BARRETT M JAMESDirector 2015-11-25Sell16,179$16.3530.76view
BARRETT M JAMESDirector 2015-11-18Sell93,000$16.6128.72view
BARRETT M JAMESDirector 2015-11-16Sell119,650$16.2431.65view
Bhatt Padmanabh P.Sr. VP of IP, CSO 2015-11-04Sell5,000$19.97.44view
Schwabe Stefan K.F.Executive Vice President R&D 2015-07-28Sell2,350$21.20.85view
PATRICK GREGORY SVP, CFO 2015-07-16Sell6,217$206.9view

Quarterly/Annual Reports about SUPN:

News about SUPN:

Articles On GuruFocus.com
Robert Bruce new Buys Feb 16 2015 
Third Quarter Was Robert Bruce's Busiest in 2014 Nov 21 2014 
Supernus Pharmaceuticals Reports Insider Buys Mar 26 2013 

More From Other Websites
ETF’s with exposure to Supernus Pharmaceuticals, Inc. : August 30, 2016 Aug 30 2016
Supernus Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SUPN-US :... Aug 29 2016
SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 24 2016
Supernus' Trokendi XR Gets FDA Nod for Migraine in Adults Aug 22 2016
Supernus Receives FDA Tentative Approval for Expanded Label of Trokendi XR® to Include Migraine... Aug 19 2016
SUPERNUS PHARMACEUTICALS INC Financials Aug 16 2016
ETF’s with exposure to Supernus Pharmaceuticals, Inc. : August 16, 2016 Aug 16 2016
Supernus Announces Resignation of Dr. James Barrett from Board of Directors; Charles W. Newhall, III... Aug 12 2016
SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers,... Aug 12 2016
Supernus Announces Resignation of Dr. James Barrett from Board of Directors; Charles W. Newhall, III... Aug 12 2016
Supernus Pharmaceuticals, Inc. :SUPN-US: Earnings Analysis: Q2, 2016 By the Numbers : August 9, 2016 Aug 09 2016
SUPERNUS PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Aug 05 2016
Edited Transcript of SUPN earnings conference call or presentation 3-Aug-16 1:00pm GMT Aug 03 2016
Supernus Pharmaceuticals Inc Earnings Call scheduled for 9:00 am ET today Aug 03 2016
Supernus tops 2Q profit forecasts Aug 02 2016
Supernus tops 2Q profit forecasts Aug 02 2016
SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 02 2016
Supernus Announces Second Quarter 2016 Financial Results Aug 02 2016
Supernus Announces Second Quarter 2016 Financial Results Aug 02 2016
2 Biotech Funds Leading Nascent Bull Market: Which Is Right For You? Aug 02 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)